Herein, we report potent in vitro and in vivo activity of TSLPRCART immunotherapy and JAK inhibition in preclinical models of CRLF2-rearranged Ph-like ALL and DS-ALL with reversible ruxolitinib-mediated suppression of TSLPRCART-induced CRS-like inflammatory responses [38, 39]. This evidence concerns the gene CRLF2 and acute lymphoblastic leukemia.